Histidine-rich glycoprotein inhibited high mobility group box 1 in complex with heparin-induced angiogenesis in matrigel plug assay

Hidenori Wake, Shuji Mori, Keyue Liu, Hideo K. Takahashi, Masahiro Nishibori

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Histidine-rich glycoprotein (HRG) is a heparin-binding glycoprotein present in plasma at 100 μg/ml. A recent study revealed that HRG suppressed heparin-dependent basic fibroblast growth factor (bFGF)-induced angiogenesis. Additionally, we reported that high mobility group box 1 (HMGB1) in complex with heparin induces angiogenesis; therefore, we examined the effect of HRG on heparin-dependent HMGB1-induced angiogenesis in the present study. HRG completely inhibited angiogenesis induced by HMGB1 in complex with heparin. HRG inhibited the diffusion of a complex of HMGB1 with heparin from matrigel into surrounding tissue. HRG also competed with HMGB1 for heparin binding in vitro. Moreover, HRG inhibited heparin-dependent vascular endothelial growth factor-A165 (VEGF-A165)-induced angiogenesis. These results strongly suggested that HRG might be an inhibitor of angiogenesis induced by growth factors with heparin binding activity and that HRG may be a potential drug for angiogenic diseases, including tumor growth.

Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalEuropean Journal of Pharmacology
Volume623
Issue number1-3
DOIs
Publication statusPublished - Nov 25 2009

Fingerprint

Heparin
matrigel
histidine-rich proteins
Angiogenesis Inhibitors
Fibroblast Growth Factor 2
Vascular Endothelial Growth Factor A
Intercellular Signaling Peptides and Proteins
Glycoproteins
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • Angiogenesis
  • Heparin
  • HMGB1
  • HRG

ASJC Scopus subject areas

  • Pharmacology

Cite this

Histidine-rich glycoprotein inhibited high mobility group box 1 in complex with heparin-induced angiogenesis in matrigel plug assay. / Wake, Hidenori; Mori, Shuji; Liu, Keyue; Takahashi, Hideo K.; Nishibori, Masahiro.

In: European Journal of Pharmacology, Vol. 623, No. 1-3, 25.11.2009, p. 89-95.

Research output: Contribution to journalArticle

@article{cdf871156a544d20a85159a8b40c6486,
title = "Histidine-rich glycoprotein inhibited high mobility group box 1 in complex with heparin-induced angiogenesis in matrigel plug assay",
abstract = "Histidine-rich glycoprotein (HRG) is a heparin-binding glycoprotein present in plasma at 100 μg/ml. A recent study revealed that HRG suppressed heparin-dependent basic fibroblast growth factor (bFGF)-induced angiogenesis. Additionally, we reported that high mobility group box 1 (HMGB1) in complex with heparin induces angiogenesis; therefore, we examined the effect of HRG on heparin-dependent HMGB1-induced angiogenesis in the present study. HRG completely inhibited angiogenesis induced by HMGB1 in complex with heparin. HRG inhibited the diffusion of a complex of HMGB1 with heparin from matrigel into surrounding tissue. HRG also competed with HMGB1 for heparin binding in vitro. Moreover, HRG inhibited heparin-dependent vascular endothelial growth factor-A165 (VEGF-A165)-induced angiogenesis. These results strongly suggested that HRG might be an inhibitor of angiogenesis induced by growth factors with heparin binding activity and that HRG may be a potential drug for angiogenic diseases, including tumor growth.",
keywords = "Angiogenesis, Heparin, HMGB1, HRG",
author = "Hidenori Wake and Shuji Mori and Keyue Liu and Takahashi, {Hideo K.} and Masahiro Nishibori",
year = "2009",
month = "11",
day = "25",
doi = "10.1016/j.ejphar.2009.09.010",
language = "English",
volume = "623",
pages = "89--95",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Histidine-rich glycoprotein inhibited high mobility group box 1 in complex with heparin-induced angiogenesis in matrigel plug assay

AU - Wake, Hidenori

AU - Mori, Shuji

AU - Liu, Keyue

AU - Takahashi, Hideo K.

AU - Nishibori, Masahiro

PY - 2009/11/25

Y1 - 2009/11/25

N2 - Histidine-rich glycoprotein (HRG) is a heparin-binding glycoprotein present in plasma at 100 μg/ml. A recent study revealed that HRG suppressed heparin-dependent basic fibroblast growth factor (bFGF)-induced angiogenesis. Additionally, we reported that high mobility group box 1 (HMGB1) in complex with heparin induces angiogenesis; therefore, we examined the effect of HRG on heparin-dependent HMGB1-induced angiogenesis in the present study. HRG completely inhibited angiogenesis induced by HMGB1 in complex with heparin. HRG inhibited the diffusion of a complex of HMGB1 with heparin from matrigel into surrounding tissue. HRG also competed with HMGB1 for heparin binding in vitro. Moreover, HRG inhibited heparin-dependent vascular endothelial growth factor-A165 (VEGF-A165)-induced angiogenesis. These results strongly suggested that HRG might be an inhibitor of angiogenesis induced by growth factors with heparin binding activity and that HRG may be a potential drug for angiogenic diseases, including tumor growth.

AB - Histidine-rich glycoprotein (HRG) is a heparin-binding glycoprotein present in plasma at 100 μg/ml. A recent study revealed that HRG suppressed heparin-dependent basic fibroblast growth factor (bFGF)-induced angiogenesis. Additionally, we reported that high mobility group box 1 (HMGB1) in complex with heparin induces angiogenesis; therefore, we examined the effect of HRG on heparin-dependent HMGB1-induced angiogenesis in the present study. HRG completely inhibited angiogenesis induced by HMGB1 in complex with heparin. HRG inhibited the diffusion of a complex of HMGB1 with heparin from matrigel into surrounding tissue. HRG also competed with HMGB1 for heparin binding in vitro. Moreover, HRG inhibited heparin-dependent vascular endothelial growth factor-A165 (VEGF-A165)-induced angiogenesis. These results strongly suggested that HRG might be an inhibitor of angiogenesis induced by growth factors with heparin binding activity and that HRG may be a potential drug for angiogenic diseases, including tumor growth.

KW - Angiogenesis

KW - Heparin

KW - HMGB1

KW - HRG

UR - http://www.scopus.com/inward/record.url?scp=70350196360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350196360&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2009.09.010

DO - 10.1016/j.ejphar.2009.09.010

M3 - Article

C2 - 19786011

AN - SCOPUS:70350196360

VL - 623

SP - 89

EP - 95

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -